Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors

Cisplatin is the main systemic treatment modality for male type II germ cell tumors (GCTs). Although generally very effective, 5%-10% of patients suffer from cisplatin-resistant disease. Identification of the driving mechanisms of resistance will enable improved risk stratification and development o...

Descripción completa

Detalles Bibliográficos
Autores principales: Timmerman, Dennis M., Eleveld, Thomas F., Sriram, Sruthi, Dorssers, Lambert C.J., Gillis, Ad J.M., Schmidtova, Silvia, Kalavska, Katarina, van de Werken, Harmen J.G., Oing, Christoph, Honecker, Friedemann, Mego, Michal, Looijenga, Leendert H.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462533/
https://www.ncbi.nlm.nih.gov/pubmed/35442716
http://dx.doi.org/10.1200/JCO.21.02809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462533/
https://www.ncbi.nlm.nih.gov/pubmed/35442716
http://dx.doi.org/10.1200/JCO.21.02809

Ejemplares similares